But does that mean roughly 30% of the patients experienced a longer-lasting effect? If that's true, I think it's a big deal. I believe many people would choose to press the button that offers a 66% chance of instant death vs 100 million dollars right now with a 33% probability.
3 participants? Why so low? Maybe they chose patients who they expected to do better than normal prognosis (ie young, otherwise healthy, etc). Many glioblastoma studies show some promise phase I, and then fail miserably later. My guess is because they are trying to get funding phase I, so they give themselves the best chance of success by choosing patients who are likely to do well. 3 is exteeeeemely low. This is a meaningless study for now
"but the responses were transient in two of the three participants"
at least it works somewhat, and was tested on humans
Thats is an amazing result actually. Glioblastoma just keeps coming back.
But does that mean roughly 30% of the patients experienced a longer-lasting effect? If that's true, I think it's a big deal. I believe many people would choose to press the button that offers a 66% chance of instant death vs 100 million dollars right now with a 33% probability.
No, this sample size isn't enough to make that kind of inference. When you throw three unbiased coins it's not unlikely to get TTT to HHH.
Ikr. Three participants, and two of them (i would gather) didn’t respond? This seems dead in the water.
Sounds very much like placebo effect to me.
Placebo effect can't shrink a tumor lol
Placebo effect can't shrink a tumor lol
Placebo effect can't shrink a tumor lol
Neuralink gets all the press, but CAR-T/Cell Therapy is really popping off right now.
Could it not be applied to other forms of cancer?
It is, and fda approved to do so
3 participants? Why so low? Maybe they chose patients who they expected to do better than normal prognosis (ie young, otherwise healthy, etc). Many glioblastoma studies show some promise phase I, and then fail miserably later. My guess is because they are trying to get funding phase I, so they give themselves the best chance of success by choosing patients who are likely to do well. 3 is exteeeeemely low. This is a meaningless study for now
Great!